サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1702634

心臓バイオインプラントデバイスの世界市場、市場規模とシェアの分析 - 成長動向と予測（2025年～2033年）

Global Cardiac Bio Implant Devices Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

出版日
ページ情報
英文 200 Pages
納期
即日から翌営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
心臓バイオインプラントデバイスの世界市場、市場規模とシェアの分析 - 成長動向と予測（2025年～2033年）
出版日: 2025年04月01日
発行: Renub Research
ページ情報: 英文 200 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の心臓バイオインプラントデバイスの市場規模は、2024年の397億6,000万米ドルから2033年までに741億米ドルに達すると予測され、2025年～2033年にCAGRで7.16%の成長が見込まれます。市場は、高齢化、患者の意識の向上、低侵襲治療オプションに対する需要の高まり、心血管疾患の有病率の上昇、インプラント技術の発展などの要因によって拡大しています。

心臓バイオインプラントデバイス市場の成長促進要因

低侵襲手術

高齢化、生活習慣の乱れ、遺伝的要因などにより、心血管疾患はより一般的なものとなりつつあり、このことが心臓バイオインプラントデバイス市場の成長を促進しています。インプラントの材料や設計における技術開発の結果、患者の転帰、デバイスの耐久性、効率のすべてが向上しています。優れた医療インフラ、患者の知識の増加、低侵襲手術の普及が需要をさらに押し上げています。強力な償還と規制の枠組み、世界中での医療費の上昇が、心臓バイオインプラント市場の成長を促進しています。

心血管疾患有病率の上昇

心臓バイオインプラント市場の拡大を後押しする重大な要因が、心血管疾患の罹患率の上昇です。冠動脈疾患などの心疾患がますます一般的になるにつれて、心臓弁、ペースメーカー、ステントに対するニーズが高まっています。米国では20歳以上の約2,010万人が冠動脈性心疾患を患っており、米国疾病予防管理センターによると、心臓発作は40秒に1回、毎年80万5,000人が発症しています。高齢化と心疾患の有病率の上昇により、バイオインプラントへのニーズは高まるとみられます。慢性心血管疾患の治療に用いる精巧なバイオインプラントへのニーズは、これらの疾患がより一般的になるにつれて高まる一方であり、市場拡大を後押しします。この健康上の負担の増大に対処するには、より長持ちする効果的なインプラントへの移行が不可欠です。

技術の進歩

心臓バイオインプラント市場の主な促進要因の1つは、技術の進歩です。材料、設計、製造技法の進歩により、より強固で効果的な生体適合性の高いインプラントが生み出されています。近年では、心臓弁、ペースメーカー、ステントのような生体インプラントは、より正確で、より小さく、患者ごとにカスタマイズされるようになり、結果が向上し、リスクが低下しています。これらのデバイスの使用は、3Dプリンティング、スマート技術、低侵襲手術法の発展によってさらに後押しされています。これらの発展は、治療効果を向上させ、心臓バイオインプラントに適した患者層を広げることで、市場の拡大を促進しています。

心臓バイオインプラントデバイス市場の課題

高いコスト

高い価格が心臓バイオインプラント市場の大きな障害となっています。バイオインプラントデバイスの高いコストは、その作成に使用される先進の技術、材料、製造技術、必要とされる特殊な手術技法によるものです。その結果、特に低所得地域や医療制度の発達していない国では、患者のアクセスが制限される可能性があります。さらに、法外な費用が保険企業や医療提供者に負担をかけ、一部の市場では命を救う心臓インプラントの広範な使用が妨げられる可能性があります。

規制上のハードル

心臓バイオインプラントデバイス部門が直面する最大の障害の1つは、規制上の障壁です。新技術の規制上の手続きは時間がかかる困難なものであるため、市場投入が延期され、最先端の治療法へのアクセスやイノベーションが遅れる可能性があります。規制当局の厳しい安全性と有効性の基準は必要なものではありますが、新製品の開発に必要な時間と費用を増加させます。小規模なメーカーや新技術は、こうした問題から特に影響を受ける可能性があり、競合を減らし、必要としている患者への有益な心臓バイオインプラントのタイムリーな提供を遅らせる可能性があります。

当レポートでは、世界の心臓バイオインプラントデバイス市場について調査し、成長促進要因と課題、各セグメントの分析、主要企業の分析などを提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 成長促進要因
  • 課題

第5章 世界の心臓バイオインプラントデバイス市場

第6章 市場シェア分析

  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別

第7章 タイプ

  • ペースメーカー
  • ICD（植込み型除細動器）
  • CRT（心臓再同期療法）

第8章 用途

  • 不整脈
  • 心筋虚血
  • 急性心筋梗塞
  • 心不全

第9章 エンドユーザー

  • 病院
  • 外来手術センター
  • 心臓カテーテル検査室
  • その他

第10章 国

  • 北米
    • 米国
    • カナダ
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • 英国
    • ベルギー
    • オランダ
    • トルコ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • タイ
    • マレーシア
    • インドネシア
    • オーストラリア
    • ニュージーランド
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • 南アフリカ
  • その他の地域

第11章 ポーターのファイブフォース分析

第12章 SWOT分析

第13章 主要企業の分析

  • F. Hoffman-La Roche
  • Eurofins Scientific
  • Illumina, Inc.
  • Natera Inc.
  • Abbott Laboratories
  • Thermo Fisher Scientific
  • Quest Diagnostics
  • Agilent Technologies
目次

Global Cardiac Bio Implant Devices Market Trends & Summary

Cardiac Bio Implant Devices Market is expected to reach US$ 74.10 billion in 2033 from US$ 39.76 billion in 2024, with a CAGR of 7.16% from 2025 to 2033. The market for cardiac bioimplants is expanding due to factors such as aging populations, improved patient awareness, growing demand for minimally invasive treatment choices, rising prevalence of cardiovascular disease, and developments in implant technology.

Cardiac Bio Implant Market Global Report by Type (Pacemaker, ICDs (Implantable Cardioverter Defibrillator), CRT (Cardiac Resynchronization Therapy)), Application (Arrhythmias, Myocardial Ischemia, Acute Myocardial Infarction, Heart Failure), End-User (Hospitals, Ambulatory Surgical Centers, Cardiac Catheterization Laboratories, Others), Countries and Company Analysis 2025-2033.

Cardiac Bio Implant Devices Industry Overview

Patients with cardiovascular disorders can benefit from cardiac bioimplants, which are medical devices that replace or support damaged heart components. These implants consist of artificial cardiac pumps, pacemakers, stents, and heart valves. The danger of rejection is reduced by the smooth integration of cardiac bioimplants, which are made of biocompatible materials. Usually, they are used to treat heart failure, arrhythmias, and aortic stenosis. Technological developments have made cardiac bioimplants more effective, long-lasting, and minimally invasive, improving patient outcomes, shortening recovery periods, and providing a better way to treat complicated cardiac disorders.

Due to aging populations, poor lifestyles, and genetic factors, cardiovascular problems are becoming more common, which is driving growth in the cardiac bioimplant devices market. Patient outcomes, device durability, and efficiency have all improved as a result of technological developments in implant materials and designs. Better healthcare infrastructure, increased patient knowledge, and the growing use of minimally invasive procedures are further driving demand. Strong reimbursement and regulatory frameworks, as well as rising healthcare costs worldwide, are all driving the cardiac bioimplant devices market's growth.

Growth Drivers for the Cardiac Bio Implant Devices Market

Minimally Invasive Procedures

Due to aging populations, poor lifestyles, and genetic factors, cardiovascular problems are becoming more common, which is driving growth in the cardiac bioimplant devices market. Patient outcomes, device durability, and efficiency have all improved as a result of technological developments in implant materials and designs. Better healthcare infrastructure, increased patient knowledge, and the growing use of minimally invasive procedures are further driving demand. Strong reimbursement and regulatory frameworks, as well as rising healthcare costs worldwide, are all driving the cardiac bioimplant devices market's growth.

Rising Cardiovascular Disease Prevalence

An important factor propelling the cardiac bioimplant devices market's expansion is the rising incidence of cardiovascular illness. The need for heart valves, pacemakers, and stents is increasing as cardiac diseases, such as coronary artery disease, become increasingly common. About 20.1 million persons in the United States who are 20 years of age or older suffer from coronary heart disease, with one heart attack every 40 seconds, or 805,000 each year, according to the Centers for Disease Control and Prevention. The need for bioimplants will increase as a result of the aging population and the rising prevalence of cardiac disease. The need for sophisticated bioimplants to treat chronic cardiovascular illnesses will only increase as these ailments become more prevalent, propelling market expansion. To address this increasing health burden, a move toward implants that are more permanent and effective will be essential.

Technological Advancements

One of the main factors propelling the market for cardiac bioimplants devices is technological advances. More robust, effective, and biocompatible implants have been created as a result of advancements in materials, design, and manufacturing techniques. These days, bioimplants-like cardiac valves, pacemakers, and stents-are more accurate, smaller, and customized for each patient, which enhances results and lowers risks. The use of these devices has been further boosted by developments in 3D printing, smart technology, and minimally invasive surgical methods. These developments are driving market expansion by improving treatment efficacy and broadening the patient base suitable for cardiac bioimplants.

Challenges in the Cardiac Bio Implant Devices Market

High costs

The market for cardiac bioimplants devices is severely hampered by high prices. The high cost of bioimplant devices is a result of the sophisticated technology, materials, and manufacturing techniques used in their creation as well as the specific surgical techniques needed. Patients' access may be restricted as a result, especially in low-income areas or nations with less developed healthcare systems. Furthermore, exorbitant expenses may put a strain on insurers and healthcare providers, preventing the broad use of life-saving cardiac bioimplants in some markets.

Regulatory Hurdles

One of the biggest obstacles facing the cardiac bioimplant devices sector is regulatory barriers. Innovation and access to cutting-edge therapies may be slowed by the drawn-out and difficult regulatory procedures for new technologies, which can postpone market introduction. Although necessary, regulatory agencies' strict safety and efficacy standards lengthen the time and expense needed to develop new products. Smaller manufacturers or emerging technologies may be especially impacted by these issues, which could reduce competition and delay the timely delivery of beneficial cardiac bioimplants to patients in need.

Cardiac Bio Implant Devices Market Overview by Regions

The market for cardiac bioimplant devices is expanding significantly on a regional basis. Because of its strong research, large prevalence of cardiovascular illnesses, and sophisticated healthcare infrastructures, North America leads the world. Europe is next, where aging populations and new technology are driving up demand. The Asia Pacific region is expanding quickly due to improved medical infrastructure, increased disease rates, and easier access to healthcare. As healthcare investments rise in Latin America and the Middle East, these regions are also growing.

United States Cardiac Bio Implant Devices Market

Due to the high frequency of cardiovascular disorders, such as heart failure and coronary heart disease, the US cardiac bioimplant market is a major global leader. Technological developments in bioimplant devices, such as heart valves, pacemakers, and stents, as well as a strong healthcare system, help the market. Impulse Dynamics approved and introduced the Optimizer Smart Mini Implantable Pulse Generator (IPG) in the United States in April 2022. By treating moderate to severe heart failure, this Class III medical device gives patients even more therapy alternatives.

The demand for cardiac bioimplants is rising due to a number of factors, including an aging population, an increase in illness rates, and growing patient awareness. Furthermore, the U.S. market is growing and innovating due to advantageous reimbursement rules, better medical infrastructure, and continuous research.

Germany Cardiac Bio Implant Devices Market

Due to a strong healthcare system and a high prevalence of cardiovascular illnesses, Germany has one of the biggest cardiac bioimplant markets in Europe. The market for pacemakers, stents, and cardiac valves is growing as a result of an aging population and rising demand for cutting-edge therapies. The adoption of novel bioimplant technologies is facilitated by Germany's emphasis on medical innovation and research as well as its advantageous reimbursement regulations. Continuous improvements in implant materials and design support expansion and enhance patient outcomes nationwide.

India Cardiac Bio Implant Devices Market

The market for cardiac bioimplants is expanding quickly in India because to the rising incidence of cardiovascular diseases (CVDs), which rank among the nation's top causes of mortality. The World Health Organization reports that more than 27% of deaths in India are caused by CVDs. The adoption of cutting-edge medical technologies, increased awareness of cardiac disease, and better healthcare infrastructure all help the industry. Because of government healthcare programs and cost reductions, bioimplants such as heart valves, pacemakers, and stents are becoming more widely available. In the upcoming years, there will likely be a significant increase in demand for cardiac bioimplants due to the growing middle class and the growing medical tourism industry.

Saudi Arabia Cardiac Bio Implant Devices Market

The market for cardiac bioimplants in Saudi Arabia is expanding quickly due to the country's high rate of cardiovascular disorders, which are a major cause of death. The need for sophisticated therapies like pacemakers, stents, and cardiac valves is growing as the population ages and the number of lifestyle-related illnesses rises. The market is expanding as a result of government investments in healthcare infrastructure and advancements in medical technology. Additionally, the use of cardiac bioimplants is accelerating throughout Saudi Arabia owing to an emphasis on patient knowledge and healthcare accessibility.

Global Cardiac Bio Implant Device Market Segments

Type

1. Pacemaker

2. ICDs (Implantable Cardioverter Defibrillator)

3. CRT (Cardiac Resynchronization Therapy)

Application

1. Arrhythmias

2. Myocardial Ischemia

3. Acute Myocardial Infarction

4. Heart Failure

End-User

1. Hospitals

2. Ambulatory Surgical Centers

3. Cardiac Catheterization Laboratories

4. Others

Countries

North America

1. United States

2. Canada

Europe

1. France

2. Germany

3. Italy

4. Spain

5. United Kingdom

6. Belgium

7. Netherlands

8. Turkey

Asia Pacific

1. China

2. Japan

3. India

4. South Korea

5. Thailand

6. Malaysia

7. Indonesia

8. Australia

9. New Zealand

Latin America

1. Brazil

2. Mexico

3. Argentina

Middle East & Africa

1. Saudi Arabia

2. UAE

3. South Africa

Rest of the World

All the Key players have been covered from 5 Viewpoints:

1. Overview

2. Key Persons

3. Product Portfolio

4. Recent Development & Strategies

5. Revenue Analysis

Key Players Analysis

1. F. Hoffman-La Roche

2. Eurofins Scientific

3. Illumina, Inc.

4. Natera Inc.

5. Abbott Laboratories

6. Thermo Fisher Scientific

7. Quest Diagnostics

8. Agilent Technologies

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Global Cardiac Bio Implant Devices Market

6. Market Share Analysis

  • 6.1 By Type
  • 6.2 By Application
  • 6.3 By End User
  • 6.4 By Countries

7. Type

  • 7.1 Pacemaker
  • 7.2 ICDs (Implantable Cardioverter Defibrillator)
  • 7.3 CRT (Cardiac Resynchronization Therapy)

8. Application

  • 8.1 Arrhythmias
  • 8.2 Myocardial Ischemia
  • 8.3 Acute Myocardial Infarction
  • 8.4 Heart Failure

9. End-User

  • 9.1 Hospitals
  • 9.2 Ambulatory Surgical Centers
  • 9.3 Cardiac Catheterization Laboratories
  • 9.4 Others

10. Countries

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
  • 10.2 Europe
    • 10.2.1 France
    • 10.2.2 Germany
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Belgium
    • 10.2.7 Netherlands
    • 10.2.8 Turkey
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Thailand
    • 10.3.6 Malaysia
    • 10.3.7 Indonesia
    • 10.3.8 Australia
    • 10.3.9 New Zealand
  • 10.4 Latin America
    • 10.4.1 Brazil
    • 10.4.2 Mexico
    • 10.4.3 Argentina
  • 10.5 Middle East & Africa
    • 10.5.1 Saudi Arabia
    • 10.5.2 UAE
    • 10.5.3 South Africa
  • 10.6 Rest of the World

11. Porter's Five Forces Analysis

  • 11.1 Bargaining Power of Buyers
  • 11.2 Bargaining Power of Suppliers
  • 11.3 Degree of Rivalry
  • 11.4 Threat of New Entrants
  • 11.5 Threat of Substitutes

12. SWOT Analysis

  • 12.1 Strength
  • 12.2 Weakness
  • 12.3 Opportunity
  • 12.4 Threat

13. Key Players Analysis

  • 13.1 F. Hoffman-La Roche
    • 13.1.1 Overview
    • 13.1.2 Key Persons
    • 13.1.3 Product Portfolio
    • 13.1.4 Recent Development & Strategies
    • 13.1.5 Revenue Analysis
  • 13.2 Eurofins Scientific
    • 13.2.1 Overview
    • 13.2.2 Key Persons
    • 13.2.3 Product Portfolio
    • 13.2.4 Recent Development & Strategies
    • 13.2.5 Revenue Analysis
  • 13.3 Illumina, Inc.
    • 13.3.1 Overview
    • 13.3.2 Key Persons
    • 13.3.3 Product Portfolio
    • 13.3.4 Recent Development & Strategies
    • 13.3.5 Revenue Analysis
  • 13.4 Natera Inc.
    • 13.4.1 Overview
    • 13.4.2 Key Persons
    • 13.4.3 Product Portfolio
    • 13.4.4 Recent Development & Strategies
    • 13.4.5 Revenue Analysis
  • 13.5 Abbott Laboratories
    • 13.5.1 Overview
    • 13.5.2 Key Persons
    • 13.5.3 Product Portfolio
    • 13.5.4 Recent Development & Strategies
    • 13.5.5 Revenue Analysis
  • 13.6 Thermo Fisher Scientific
    • 13.6.1 Overview
    • 13.6.2 Key Persons
    • 13.6.3 Product Portfolio
    • 13.6.4 Recent Development & Strategies
    • 13.6.5 Revenue Analysis
  • 13.7 Quest Diagnostics
    • 13.7.1 Overview
    • 13.7.2 Key Persons
    • 13.7.3 Product Portfolio
    • 13.7.4 Recent Development & Strategies
    • 13.7.5 Revenue Analysis
  • 13.8 Agilent Technologies
    • 13.8.1 Overview
    • 13.8.2 Key Persons
    • 13.8.3 Product Portfolio
    • 13.8.4 Recent Development & Strategies
    • 13.8.5 Revenue Analysis